Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report

Med Oncol. 2013;30(2):568. doi: 10.1007/s12032-013-0568-x. Epub 2013 Apr 7.

Abstract

Chemotherapy-induced thrombotic microangiopathy is a severe illness that has occurred in a small number of patients treated with carboplatin and combination of docetaxel and trastuzumab chemotherapy. We describe herein the case of a patient with stage IIB breast cancer who developed thrombotic microangiopathy after five cycles of carboplatin, docetaxel, and trastuzumab.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / blood*
  • Breast Neoplasms / drug therapy*
  • Carboplatin / administration & dosage
  • Carboplatin / adverse effects
  • Chemotherapy, Adjuvant
  • Docetaxel
  • Female
  • Humans
  • Middle Aged
  • Receptor, ErbB-2 / biosynthesis
  • Taxoids / administration & dosage
  • Taxoids / adverse effects
  • Thrombotic Microangiopathies / chemically induced*
  • Trastuzumab

Substances

  • Antibodies, Monoclonal, Humanized
  • Taxoids
  • Docetaxel
  • Carboplatin
  • Receptor, ErbB-2
  • Trastuzumab